TL1A, commonly called TNFSF15, belongs to the tumor necrosis factor family. TL1A is expressed in a variety of immune cells, including monocytes, macrophages, dendritic cells, T cells, and others.
TL1A is encoded by TNFSF15 and is produced by endothelial cells. 5 Expression of TL1A can be induced in endothelial cells and chondrocytes under the influence of the inflammatory cytokines TNF and ...
Hosted on MSN3mon
Spyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A antibodiesUS-based biotechnology company Spyre Therapeutics has begun dosing healthy volunteers in Phase I studies of two investigational monoclonal antibodies. The drug candidates SPY002-091 and SPY002-072 ...
Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...
In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...
Hosted on MSN1y
Generic Drug Player Teva Pharma To Divest Its Active Pharmaceutical Ingredient Business, Q4 Earnings Surpass EstimatesThis increase was mainly due to an upfront payment of $500 million in connection with the collaboration on anti-TL1A asset, the sale of certain product rights, higher revenues from generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results